Plasma No Longer Has to Wait in the Freezer: FDA Approves First Freeze-Dried Product, EZPLAZ

Severe bleeding often leaves medical teams no time to wait for plasma to thaw. The U.S. Food and Drug Administration (FDA) has approved EZPLAZ freeze-dried plasma for use in adults, providing a rapidly reconstituted emergency option for patients who need multiple coagulation factors but cannot access other plasma products. According to developer Teleflex, it is the first freeze-dried plasma product authorized by the FDA in the United States.

EZPLAZ was developed by Vascular Solutions, a Teleflex subsidiary. Its indicated uses include multiple coagulation factor deficiencies caused by massive transfusion, liver disease, or disseminated intravascular coagulation, as well as the need to rapidly reverse the effects of warfarin in patients who are bleeding or require an urgent invasive procedure. The approval has clear limits: it must be used when plasma is needed and other plasma products are unavailable. It is not a comprehensive replacement for fresh frozen plasma or a treatment for specific coagulation deficiencies.

Conventional plasma requires frozen storage, thawing equipment, and subsequent refrigeration, limiting its deployment in ambulances, remote areas, and battlefield settings. EZPLAZ is packaged in a flexible plastic bag, and the kit includes sterile water for injection. Company data show that the product can be stored at 2–25°C for 12 months and reconstituted in approximately 1 to 2.5 minutes. These features transform plasma from a resource highly dependent on the cold chain into a blood product that can be carried more readily with emergency equipment.

The early human studies supporting the technology remain small. A Phase 1 trial published in 2021 enrolled 24 healthy volunteers, who sequentially received 270, 540, or 810 milliliters of autologous freeze-dried plasma. The highest-dose group also compared freeze-dried plasma with fresh frozen plasma using a randomized crossover design. The study found no dose-limiting toxicity, deaths, or serious adverse events determined to be related to freeze-dried plasma. The clinical-use product took an average of approximately 67 seconds to reconstitute.

Researchers also compared 155 paired samples of frozen plasma and the resulting freeze-dried product. The results showed that multiple coagulation factors, clotting times, and key quality indicators were generally preserved. However, the trial used autologous plasma from healthy participants and was primarily intended to assess safety, rather than demonstrate that the product improves survival or hemostatic outcomes in patients with traumatic bleeding. Its results cannot be directly equated with clinical effectiveness in emergency and critical care settings.

EZPLAZ also retains the inherent risks of conventional plasma transfusion, including hemolytic reactions caused by blood-group incompatibility, transfusion-related acute lung injury, allergic reactions up to and including anaphylactic shock, and the theoretical transmission of infections. It must not be used in people with IgA deficiency or those who have previously had an allergic reaction to fresh frozen plasma, liquid plasma, or plasma-derived products.

The FDA also requires a Phase 4 trial to further assess thrombosis and thromboembolic events. This approval first addresses whether plasma can reach patients more quickly, rather than eliminating the uncertainties inherent in transfusion itself. How freeze-dried products affect blood-use workflows, hemostatic effectiveness, and serious complications in the real world remains to be answered by post-approval data.